experiment was designed to examine the effect of the depletion of noradrenaline, a neurotransmitter thought to stimulate GRF release, in 3 groups of animals. Group 1 received two ip injections of vehicle saline, one at 1700 h the day before the experiment, and the other at 0830 h on the day of the experiment. Following the same time schedules, Group 2 were given saline followed by diethyldithiocarbamate (DDC, 750 mg/kg), a dopamine fl-hydroxylase inhibitor (Sigma Chemical Co., St. Louis MO), and Group 3 received two injections of a-methyl-p-tyrosine (ctMPT, 250 mg/ kg), a tyrosine hydroxylase inhibitor (Sigma Chemical Co.). In the third experiment, the rats were injected ip with saline or DDC at 0830 h. The DDC-treated rats were then injected sc with either human GRF(1-44)-NH2 (10 gig/kg; Sumitomo Pharmaceutical Co., Ltd., Osaka, Japan) or 0.25% BSA in vehicle saline 3 times at 3.5-h intervals, i.e. at 0830, 1200, and 1530 h, which corresponded to the time of onset of spontaneous GRF-dependent GH pulses in our laboratory [2, 5] . The control rats received vehicle sc 3 times. All rats were killed by decapitation at 1630 h, and the anterior pituitaries were obtained for extraction of RNA as described [7] . Pituitary GRF receptor and J3-actin mRNA levels were determined by RNase protection assays as described [8, 9] . The intensity of GRF receptor mRNAs were expressed relative to the /3-actin mRNA levels in each sample. The results are presented as the means ± SEM. Two-way analysis of variance followed by Duncan's multiple range test were used for the statistical analysis. A P value of <0.05 was considered to be significant.
Results Figure 1 shows the protected mRNA fragments of GRF receptor and f3-actin in the anterior pituitaries of rats passively immunized with rat GRF antiserum or NRS. The administration of antiserum increased GRF receptor mRNA levels in a dose-related manner. The mean values for GRF receptor mRNA in 0.25 and 1.0 ml antiserumtreated groups were 264 ± 27% (P<0.01) and 382 ± 41% (P<0.01) of the control NRS-treated levels (n=5 rats/group).
As shown in Fig. 2 , both DDC and aMPT treatment also caused a significant increase in GRF receptor mRNA to 313 ± 32% (P<0.01) and 294 ± 42% (P<0.01), respectively, of the control levels, which were not statistically different in the two groups (n=9 animals/group).
As shown in Fig. 3 Effects of rat GRF antiserum on pituitary GRF receptor (GRF-R) mRNA levels. Protected GRF and fi-actin mRNA bands in 3 representative rats are shown in NRS (normal rabbit serum) and 0.25 and 1.0 ml antiserum-treated groups. Means ± SEM levels of GRF-R mRNA, obtained in two separate experiments, are shown as columns, with the control (NRS) value being 100%. n=5 animals per group. *P<0.01 vs. NRS. 
Changes in pituitary
GRF receptor (GRF-R) mRNA levels following DDC and aMPT treatment. Three protected GRF-R and /3-actin mRNA bands are shown in each group. Results from three separate experiments were combined and are shown as columns, with the mean control value being 100%. n=9 rats/group. *P<0 .01 vs. control. recycling and synthesis.
We wished to examine whether down-regulation of GRF receptors by GRF takes place at a gene expression level. There is abundant evidence that activation of noradrenergic a-adrenoreceptors facilitates GRF release. a-adrenoreceptor agonists, clonidine and guanfacine, stimulate GRF release [2, 11] , whereas a-adrenoreceptor blocker, phenoxybenzamine, completely inhibits GRFdependent, spontaneous GH pulses [12] , as do DDC and aMPT [13, 14] . The up-regulation of GRF receptor gene expression in the DDC-treated rats was reversed by replacement with GRF, which was given 3 times at 3.5-h intervals, corresponding to the times of onset of physiological GRF-dependent GH surges [2, 5] . The sc dose of GRF was chosen on the basis of the results from pilot experiments to be 10 , tg/kg, a dose ten times higher than that previously used for intravenous injection [5, 6] . This finding demonstrates that exogenous GRF can down-regulate its own receptor gene expression.
Our results indicate that increased or reduced GRF receptor mRNA accumulation is at least one important mechanism in up-or down-regulation, respectively. Of great importance is the finding that the GRF receptor mRNA levels were noticeably up-regulated in the absence of GRF, which suggests that the down-regulatory mechanism is operating under physiological conditions. Changes in GRF receptor expression could result in altered binding of the ligand, as our receptor probe was designed to recognize the N-terminal extracellular region [8] , presumed to represent the ligand-binding domain [1] . Therefore, the regulation of GH secretion at the pituitary GRF receptor level would play an important role in the control of the hypothalamic GRF-pituitary GH axis. 
